Navigation Links
Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study
Date:7/14/2009

GOTHENBORG, Sweden, July 14 /PRNewswire/ -- PharmaSurgics AB. successfully completes Phase I clinical study showing their novel candidate drug PXL01 is safe and well tolerated. Initially developed to prevent post-surgical adhesion formation following hand surgery the product combines the pharmacological effect of PXL01 with the physical barrier effect of the vehicle, and has the potential to be the first anti-adhesion drug on the market. 'These results provide the foundation for proceeding to the next phase, proof of concept study in patients,' said Fredrik Sjovall, CEO of PharmaSurgics, adding 'the proof of concept study in patients of flexor tendon repair surgery is scheduled to start in December 2009.'

Post-surgical adhesions are bands of scar tissue connecting anatomic sites in the body that should not normally be connected. These develop after almost every type of surgery and cause symptoms such as restricted joint mobility, chronic pain, intestinal obstruction and re-operative complications. Following flexor tendon repair surgery post-surgical adhesions lead to decreased strength and function of the affected joints, extensive post-operative physiotherapy and extended periods of sick leave.

About PharmaSurgics

PharmaSurgics in Sweden AB is a Gothenburg based biotech company that develops and commercializes a novel treatment for preventing harmful scarring and promoting wound healing after surgery. PharmaSurgics product concept is based on proprietary synthetic peptides which have strong anti-inflammatory and anti-infectious properties. The company was founded in 2005, based on extensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarker at Sahlgrenska University Hospital, Gothenborg, Sweden. PharmaSurgics is a Karolinska Development portfolio company.

    For further information please contact
    Fredrik Sjovall, CEO of PharmaSurgics
    Ph: +46-31-762-29-01
    Email: fredrik@pharmasurgics.se


'/>"/>
SOURCE PharmaSurgics AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours
2. Novel gene found for dilated cardiomyopathy
3. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
4. Novel method predicts impact of a covert anthrax release
5. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
6. Novel handheld device detects anthrax with outstanding accuracy and reliability
7. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
8. Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia
9. Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
10. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
11. Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), ... Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will ... “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment industries. ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
Breaking Biology Technology:
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric ... ... DERMALOGs Face Matching enables to match face pictures ... the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
(Date:3/7/2017)... LAKE CITY , March 7, 2017   ... that help top global companies identify the best talent, ... as Chief Sales Officer (CSO) and Diana ... Kucer,s appointments round out a seasoned executive team poised to ... and beyond, building on a year of record bookings ...
Breaking Biology News(10 mins):